Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The SURPASS clinical trial programme has provided evidence of these metabolic improvements, though it's important to note that long-term cardiovascular outcome studies are ongoing, and Mounjaro does not currently have a UK-licensed indication for cardiovascular risk reduction
Cardio 150+ minutes weekly (or 75 minutes of vigorous activity) improves cardiovascular function and creates the calorie deficit that medication was helping sustain
doi: 10.3390/antiox12040972 335 RossiMBosettiCNegriELagiouPVecchiaCL
Overweight and obesity management (NG246) Medicines and surgery NICE
Tirzepatide is a dual GLP-1 and GIP receptor agonist that works faster than single-mechanism medicationsclinical trials show average weight loss of 15% to 22% within 68 weeks
Attention deficit hyperactivity disorder: diagnosis and management (NG87) NICE
US$ 22.23
US$ 24.56
US$ 27.84
US$ 23.46
US$ 27.27
US$ 22.56
